Research Activity – Page 6

ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot

1 month ago talkbio0Tagged AB-2100, ArsenalBio, Cell Therapy, Clinical Trials, layoffs, Myers, restructuring, Squibb partnership, Staff

ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership

AstraZeneca’s Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment

1 month ago talkbio0Tagged anifrolumab, AstraZeneca, Clinical Trials, disease activity, Encephalitis, St. Louis, Lupus Erythematosus, Systemic, Phase III, Saphnelo, Self-Injectable, subcutaneous, TULIP-SC trial

AstraZeneca; Saphnelo; anifrolumab; Phase III; TULIP-SC trial; systemic lupus erythematosus; SLE; self-injectable; subcutaneous; clinical trial; disease activity reduction

Priovant Announces Successful Phase III Results for Brepocitinib in Dermatomyositis (VALOR Study)

1 month ago talkbio0Tagged Brepocitinib, Clinical Trials, cutaneous remission, Dermatomyositis, NDA filing, Phase III, Priovant, Roivant, Steroids, Total Improvement Score, Tumor stage Tis, VALOR study

Priovant; Roivant; brepocitinib; Phase III; VALOR study; dermatomyositis; clinical trial; Total Improvement Score; TIS; steroid reduction; cutaneous remission; NDA filing

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

1 month ago talkbio0Tagged Ang2, Biosciences, Clinical Trials, Disorder of eye, Macular edema due to diabetes mellitus, Ollin, OLN324, Roche (company), Vabysmo, Vascular Endothelial Growth Factor A, Wet AMD

Ollin Biosciences; Roche; eye disease; biotech; VEGF-A; Ang2; wet AMD; diabetic macular edema; clinical trial; OLN324; Vabysmo

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

1 month ago talkbio0Tagged Approved, Clinical Trials, icotrokinra, inhibitors, interleukin-23, next-generation biologics, oral peptides, Piclidenoson, TYK2 gene, United States Food and Drug Administration, Vunakizumab

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

1 month ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal

1 month ago talkbio0Tagged AI/ML-enabled product, Collaboration, Drug Discovery, engine, immune-mediated diseases, milestone payments, molecular glue degraders, Monte Rosa Therapeutics, MRT-6160, Novartis, VAV1 protein

Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine

FibroGen Settles with SEC for $1.25M Over Roxadustat Data Tampering Allegations

2 months ago talkbio0Tagged Anemia, cardiovascular safety, Clinical Trials, data manipulation, FibroGen, Kin-Hung Peony Yu, Phase 3, roxadustat, seconds, settlement, United States Food and Drug Administration

FibroGen; SEC; roxadustat; data manipulation; settlement; Kin-Hung Peony Yu; phase 3 clinical trial; anemia drug; cardiovascular safety; FDA

Intercept Withdraws Ocaliva from US Market After FDA Safety Concerns

2 months ago talkbio0Tagged Clinical Trials, concerns, Drug withdrawal syndrome, Injury of liver, Intercept Pharmaceuticals, Liver diseases, Ocaliva, Primary Biliary Cholangitis, regulatory setbacks, Safety, United States Food and Drug Administration

Intercept Pharmaceuticals; Ocaliva; liver disease; primary biliary cholangitis; FDA; drug withdrawal; safety concerns; liver injury; clinical trial hold; regulatory setbacks

Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment

2 months ago talkbio0Tagged Biological Science Disciplines, Brexit impact, Drug Discovery, Government, Investments, layoffs, London Bioscience Innovation Centre, Merck, Multiple Sulfatase Deficiency Disease, Relocation of home or business, UK

Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs